Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
The Tumour Cell
Domenico Ribatti,Enrico Crivellato +1 more
- 01 Jan 2011
TL;DR: The main implication of this assertion is that tumour cells have the twofold tendency to escape division control and invade neighbouring tissues as well as colonize at distance.
9
Role of Mast Cells in Angiogenesis
Enrico Crivellato,Domenico Ribatti +1 more
- 01 Jan 2013
TL;DR: This chapter will focus on the specific role of MCs in the different types of angiogenic processes, including angiogenesis that accompanies inflammation and tumour-associated angiogenicity.
9
Erythropoietin and cancer, a double-edged sword.
TL;DR: This editorial is focused on the double controversial action of erythropoietin, acting as anticancer agent and as a promoting cancer agent.
9
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma
Diego Guidolin,Roberto Tamma,Tiziana Annese,Cinzia Tortorella,Giuseppe Ingravallo,Francesco Gaudio,Tommasina Perrone,Pellegrino Musto,Giorgina Specchia,Domenico Ribatti +9 more
TL;DR: In this paper, the authors evaluated tumor T, B cells, macrophages and mast cells distribution in GBC and ABC DLBCL subgroups through a set of morphometric parameters allowing to provide a quantitative evaluation of the morphological features of the spatial patterns generated by these inflammatory cells.
Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients
TL;DR: The current knowledge of the involvement of host-related factors, including innate and adaptive immunity in orchestrating the tumor cell fate and the primary resistance mechanisms to immunotherapy in NSCLC are highlighted.
9